Everyday more than 45 men are diagnosed with prostate cancer in Australia.
Androgen Deprivation Therapy (ADT) is a potent anti-cancer therapy that reduces prostate cancer mortality. However, ADT may increase the risk of cardiovascular morbidity and mortality.
The purpose of this research trial is to evaluate the impact of ADT on cardiovascular structure and function, as well as the impact of exercise training during ADT on cardiovascular structure and function.
Enquire about participating in this trial
Who can participate?
- Men 40 years or older.
- Diagnosed with prostate cancer.
- Scheduled or within one-month of receiving ADT.
Benefits of participation
- Comprehensive cardiovascular screening including echocardiography, cardiac magnetic resonance imaging and cardiopulmonary exercise test.
- 3-month best practice exercise intervention.
- Supervised by an accredited exercise physiologist who specialises in prostate cancer.
- Individualised exercise prescriptions.
- Small group exercise sessions.
- Delivered at one of four fitness centres around Melbourne.
- All screening and training is provided free of charge to participants.
- All participants will receive the exercise intervention with the control group offered a delayed intervention (wait list control).
If you are interested in participating or would like further information, please contact:
Ashley Bigaran
T 03 8532 1108
E Ashley.Bigaran@baker.edu.au
